ARTICLE

Pharma Ignite | SCRIP
Industry News & Insights

The Quiet Shift Reshaping **Metabolic Trial Execution**

By Izabela Chmielewska, Editor in Chief of Custom Content, Citeline | FEBRUARY 2026



The Quiet Shift Reshaping Metabolic Trial Execution

As investment in metabolic and obesity therapeutics continues to accelerate, sponsors are encountering a familiar tension: the science is moving faster than the operational models designed to test it. Late-stage trials are becoming longer, more complex, and increasingly focused on chronic use, yet many protocols still rely on assumptions rooted in short-term efficacy and site-centric execution.

For developers now thinking beyond initial weight loss, those assumptions are beginning to fray, prompting a reassessment of what clinical support is needed to run metabolic trials effectively – and where those capabilities should reside.

One area drawing renewed attention is nutrition.

According to Betsy Curry, associate director of clinical assignment at EmVenio Clinical Research, metabolic trials are no longer designed around weight loss alone. “While weight remains important, researchers are looking at additional factors like quality of life and broader health markers,” she says, further noting that the idea that “BMI alone doesn’t tell the full story” and is now widely recognized.

That shift has been evident across recent late-stage metabolic programs. Sponsors and investigators are increasingly incorporating outcomes that extend beyond weight change, including cardiometabolic risk factors and measures of sustained health impact. This broader approach is reflected in the evidence supporting GLP-1 receptor agonists such as semaglutide, which have shown improvements in patient-reported outcomes and cardiometabolic parameters alongside weight loss[1].

Nutrition Enters Trial Design

In many metabolic trials, lifestyle and nutrition support have traditionally played a secondary role. Even when included, they have not always been treated as core components of protocol execution. As trial designs evolve, that distinction is becoming more difficult to maintain.

Curry points to participation burden as a key driver of retention. Anything that “makes it easier for a patient to participate” can support protocol compliance, she says, while disruption to daily routines increases the risk of losing participants over time.

This concern has become more acute as sponsors contend with enrollment delays and retention risk in longer-running metabolic trials, particularly among populations with limited access to traditional research sites[2]. Regulatory guidance has increasingly emphasized participation burden and access as key contributors to dropout risk, underscoring the rising cost of losing participants partway through a study.

Nutrition support, when delivered consistently, can help mitigate that risk. Integrating it at scale, however, introduces its own operational challenges.

> “Regulatory guidance has increas-ingly emphasized participation burden and access as key contributors to trial dropout risk.”

Scaling Without Friction

From a clinical operations perspective, Curry points to the tension between personalization and standardization as one of the most difficult aspects of integrating nutrition into large trials. “Nutrition and lifestyle support work best

when participants feel a sense of connection and accountability without feeling overwhelmed," she says. However, creating that right balance across thousands of participants over several years is complex.

Protocols must be standardized, yet food choices are culturally and regionally specific. As a result, technology platforms must be secure, accessible, and simple enough for broad use. Credential requirements for clinicians also vary by country, adding regulatory complexity to multi-national studies.

"Adding a new clinician type isn't as simple as it sounds," Curry notes. "It involves multiple layers: data privacy, technology integration, and legal compliance across different countries."

This complexity is one reason sponsors have historically been cautious about expanding lifestyle components within trials. Without clear governance and infrastructure, support intended to improve engagement can quickly become an operational burden.

> Adding a new clinician type isn't as simple as it sounds. It involves multiple layers: data privacy, technology integration, and legal compliance across different countries. - Betsy Curry, Associate Director of Clinical Assignment, EmVenio Clinical Research

Delivery Moves Beyond The Clinic

One factor beginning to shift that calculus is the normalization of decentralized and community-based trial models. Mobile and virtual visits, once seen as a contingency solution, are now an accepted part of trial design, particularly in chronic disease research.

For registered dietitians, virtual engagement has altered how support is delivered. Curry describes virtual visits as a game-changer for metabolic trials, noting that increased scheduling flexibility can improve patient adherence.

These visits also provide insight that is often missing from clinic-based interactions. "Even virtual visits reveal context, like family dynamics or distractions," she adds. "Which helps to tailor support in a way that feels realistic."

Community-based approaches extend that visibility further, particularly for participants who would otherwise struggle to access traditional sites. As sponsors face growing pressure to improve inclusion and retention, proximity and convenience are becoming operational considerations rather than optional enhancements.

Introducing New Clinician Roles At Scale

Despite growing interest in expanding clinical support models, sponsors remain cautious about introducing new clinician types into active trials. Regulatory frameworks, such as the ICH E6 Good Clinical Practice (GCP) Guideline[3], reinforce sponsor accountability in overseeing trial conduct across distributed models. Against that backdrop, adding new clinician roles mid-study is rarely viewed as a low-risk change.

'Registered dietitians' is a protected professional title, with specific education and certification requirements that Curry states are important for quality and compliance in regulated research settings.

There is also the question of timing. Sponsors are understandably wary of changes that could delay study startup or disrupt visit schedules, particularly once protocols are active. However, recent experience suggests that, with sufficient planning, integrating new clinician roles can be done without sacrificing speed.

That tension is illustrated in EmVenio's Metabolic Case study[4], which details a Phase III metabolic trial conducted across the US, Canada, and Puerto Rico. In this study, registered dietitians were introduced as a new clinician type to support health behavior and lifestyle assessments. Registered dietitians were introduced early in the study to support health behavior and lifestyle assessments, with no missed visits reported during the initial deployment phase.

For Curry, the significance lies less in the headline timing metric and more in what it demonstrates operationally: that specialist clinician roles can be integrated efficiently when governance, training, and oversight are addressed upfront rather than retrofitted later.

Culture As A Driver Of Engagement

Cultural context has also emerged as a practical consideration in delivering nutritional support in metabolic trials. Local norms and daily routines shape food choices, and generic guidance does not always translate well across diverse participant populations.

Curry is direct on this point: "Food is cultural," she says. "Matching participants with dietitians who understand their food norms makes a difference."

In practice, she notes, cultural alignment can influence how participants engage with lifestyle guidance over time. When nutrition advice reflects familiar foods and routines, relationships tend to be easier to establish and sustain. In long-running metabolic studies, that consistency can play an important role in supporting retention. More broadly, this reflects a growing recognition that trial execution needs to mirror real-world care. As metabolic therapies move toward broader and more heterogeneous populations, trial credibility hinges on how well studies reflect the realities of daily life.

> Specialist clinician roles can be integrated efficiently when governance, training, and oversight are addressed upfront rather than retrofitted later.

Implications For Future Metabolic Trials

Questions about where nutrition expertise fits into metabolic trial execution are starting to surface. Registered dietitians have traditionally been positioned around individual counseling, but Curry suggests that framing may be too narrow.

"We've only scratched the surface," she says. "Beyond counseling, dietitians can play a role in community outreach and patient recruitment."

From a sponsor perspective, that possibility introduces familiar considerations. Nutrition is widely acknowledged as relevant in metabolic research, but integrating additional expertise into active studies raises practical questions around governance, oversight, and risk. As trials extend in duration and place greater emphasis on adherence and longer-term outcomes, lifestyle support intersects more directly with day-to-day execution rather than sitting alongside it.

Whether that integration becomes more routine remains an open question. Sponsors will be looking for evidence that these approaches can be implemented consistently, remain compliant, and support existing timelines. In an increasingly competitive metabolic landscape, those factors are likely to shape how far and how fast nutrition support is embedded in future trial designs.

Sources

- ***1 Citeline. Late-stage GLP-1 drug trials move beyond weight loss as sponsors assess durability and broader metabolic outcomes. In Vivo*** https://insights.citeline.com/in-vivo/market-intelligence/late-stage-glp-1-drug-trials-outside-the-cardiometabolic-space-LUW7L2PDKVD2TL4ZFM3J33B6KQ/?
- ***2 U.S. Food and Drug Administration. Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs.*** (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing- participation-clinical-trials-eligibility-criteria-enrollment-practices-and-trial-design)
- ***3 ICH E6(R3) Guideline for Good Clinical Practice.*** (https://www.ich.org/page/efficacy- guidelines)
- ***4*** EmVenio Research. ***Metabolic Case Study: Integrating registered dietitians into a Phase III metabolic trial.***

EmVenio™

EmVenio is a global leader in clinical research, committed to helping researchers make medical breakthroughs. Delivering consistent results and making research available for all starts with meeting patients where they are—in their homes, in their communities, or where they gather.

Through our mobile teams, virtual visits, and local research sites, we achieve precise, reliable data, and consistent results that meet and exceed research goals. We have research capabilities extending over 80 countries, enabling us to continually enroll populations others miss and create a more complete picture for scientific advancement.

Learn more at https://www.emvenio.com.

Pharma Ignite

Pharma Ignite brings you the most up-to-date and informed intelligence in the industry. Our network of industry-leading analysts and partners is pursuing new intelligence in the core areas of life sciences using Citeline's suite of insights products and services - all of which has the power to fuel your organization and projects. We also provide cutting-edge lead generation and brand programmes to help you reach and collaborate with audiences across industry events and digital platforms.

CITELINE

Citeline (a Norstella Company) powers a full suite of complementary business intelligence offerings to meet the evolving needs of health science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial, and regulatory related-decisions and create real-world opportunities for growth. Our global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more.